SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jmt who wrote (3316)7/17/1998 7:06:00 PM
From: R>G>  Read Replies (1) of 5402
 
JMT Can you clarify your statement? But he has not engineered this product. He is simply marketing a product which has been tested and rejected in the past.

1. Difference between first generation and second generation drug.
Both drugs use an emulsion. In Japan's version 1st generation drug they used 2 flurocarbons, 8 adjuvent solutions, and 2 surfactants. Sanguine's 2nd generation drug uses 1 flurocarbon and 1 surfactant. This version is a much cleaner product.
Another very important thing to remember is that with this being a 2nd generation drug the time frame for approval should be much shorter. It took about 10 years when Dr. Drees was head of Alpha ( US subsidiary of Green Cross) to get FDA approval. Now that the 1st generation drug has been tested on approximately 13,000 people and saved lives, the process should be quicker, cheaper, and smoother. He is hoping for FDA approval in 3 years.

This is not the same product!!!!!!!!

2. You say this product was rejected in the past. I am not familiar with it ever being rejected. Can you clarify??

3. This product is being worked on as we speak. There are about 9 variations of this product that are being worked on. There is about a 80/20% ratio for this product, what they are working on now is slightly changing the ratio to find the best one, say 83/17 %or 78/22%,etc etc.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News